vs
德康医疗（DXCM）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是SCANSOURCE, INC.的1.6倍（$1.3B vs $766.5M），德康医疗净利率更高（21.2% vs 2.2%，领先19.1%），德康医疗同比增速更快（21.6% vs 2.5%），过去两年德康医疗的营收复合增速更高（12.0% vs 0.9%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
DXCM vs SCSC — 直观对比
营收规模更大
DXCM
是对方的1.6倍
$766.5M
营收增速更快
DXCM
高出19.0%
2.5%
净利率更高
DXCM
高出19.1%
2.2%
两年增速更快
DXCM
近两年复合增速
0.9%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $766.5M |
| 净利润 | $267.3M | $16.5M |
| 毛利率 | 62.9% | 13.4% |
| 营业利润率 | 25.6% | 2.3% |
| 净利率 | 21.2% | 2.2% |
| 营收同比 | 21.6% | 2.5% |
| 净利润同比 | 153.6% | -3.3% |
| 每股收益（稀释后） | $0.67 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMSCSC
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $766.5M | ||
| Q3 25 | $1.2B | $739.6M | ||
| Q2 25 | $1.2B | $812.9M | ||
| Q1 25 | $1.0B | $704.8M | ||
| Q4 24 | $1.1B | $747.5M | ||
| Q3 24 | $994.2M | $775.6M | ||
| Q2 24 | $1.0B | $746.1M |
净利润DXCMSCSC
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $16.5M | ||
| Q3 25 | $283.8M | $19.9M | ||
| Q2 25 | $179.8M | $20.1M | ||
| Q1 25 | $105.4M | $17.4M | ||
| Q4 24 | $151.7M | $17.1M | ||
| Q3 24 | $134.6M | $17.0M | ||
| Q2 24 | $143.5M | $16.1M |
毛利率DXCMSCSC
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | 13.4% | ||
| Q3 25 | 60.5% | 14.5% | ||
| Q2 25 | 59.5% | 12.9% | ||
| Q1 25 | 56.9% | 14.2% | ||
| Q4 24 | 58.9% | 13.6% | ||
| Q3 24 | 59.7% | 13.1% | ||
| Q2 24 | 62.4% | 13.0% |
营业利润率DXCMSCSC
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 2.3% | ||
| Q3 25 | 20.1% | 3.5% | ||
| Q2 25 | 18.4% | 3.3% | ||
| Q1 25 | 12.9% | 3.2% | ||
| Q4 24 | 17.0% | 2.5% | ||
| Q3 24 | 15.3% | 2.3% | ||
| Q2 24 | 15.7% | 2.9% |
净利率DXCMSCSC
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 2.2% | ||
| Q3 25 | 23.5% | 2.7% | ||
| Q2 25 | 15.5% | 2.5% | ||
| Q1 25 | 10.2% | 2.5% | ||
| Q4 24 | 13.6% | 2.3% | ||
| Q3 24 | 13.5% | 2.2% | ||
| Q2 24 | 14.3% | 2.2% |
每股收益（稀释后）DXCMSCSC
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.75 | ||
| Q3 25 | $0.70 | $0.89 | ||
| Q2 25 | $0.45 | $0.87 | ||
| Q1 25 | $0.27 | $0.74 | ||
| Q4 24 | $0.37 | $0.70 | ||
| Q3 24 | $0.34 | $0.69 | ||
| Q2 24 | $0.35 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $910.9M |
| 总资产 | $6.3B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMSCSC
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $83.5M | ||
| Q3 25 | $1.8B | $124.9M | ||
| Q2 25 | $1.2B | $126.2M | ||
| Q1 25 | $904.9M | $146.3M | ||
| Q4 24 | $606.1M | $110.5M | ||
| Q3 24 | $621.2M | $145.0M | ||
| Q2 24 | $939.2M | $185.5M |
股东权益DXCMSCSC
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $910.9M | ||
| Q3 25 | $2.7B | $914.0M | ||
| Q2 25 | $2.6B | $906.4M | ||
| Q1 25 | $2.3B | $901.7M | ||
| Q4 24 | $2.1B | $900.7M | ||
| Q3 24 | $2.0B | $920.9M | ||
| Q2 24 | $2.4B | $924.3M |
总资产DXCMSCSC
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $1.7B | ||
| Q3 25 | $7.5B | $1.7B | ||
| Q2 25 | $7.3B | $1.8B | ||
| Q1 25 | $6.8B | $1.7B | ||
| Q4 24 | $6.5B | $1.7B | ||
| Q3 24 | $6.4B | $1.8B | ||
| Q2 24 | $6.8B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $30.8M |
| 自由现金流经营现金流 - 资本支出 | — | $28.9M |
| 自由现金流率自由现金流/营收 | — | 3.8% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXCMSCSC
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $30.8M | ||
| Q3 25 | $659.9M | $23.2M | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $183.8M | $66.1M | ||
| Q4 24 | $301.4M | $-6.2M | ||
| Q3 24 | $199.5M | $44.8M | ||
| Q2 24 | $279.4M | — |
自由现金流DXCMSCSC
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $28.9M | ||
| Q3 25 | $579.4M | $20.8M | ||
| Q2 25 | $208.9M | — | ||
| Q1 25 | $96.8M | $64.6M | ||
| Q4 24 | $176.8M | $-8.2M | ||
| Q3 24 | $88.3M | $42.5M | ||
| Q2 24 | $213.3M | — |
自由现金流率DXCMSCSC
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 3.8% | ||
| Q3 25 | 47.9% | 2.8% | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 9.3% | 9.2% | ||
| Q4 24 | 15.9% | -1.1% | ||
| Q3 24 | 8.9% | 5.5% | ||
| Q2 24 | 21.2% | — |
资本支出强度DXCMSCSC
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 0.3% | ||
| Q3 25 | 6.7% | 0.3% | ||
| Q2 25 | 8.1% | 0.3% | ||
| Q1 25 | 8.4% | 0.2% | ||
| Q4 24 | 11.2% | 0.3% | ||
| Q3 24 | 11.2% | 0.3% | ||
| Q2 24 | 6.6% | 0.2% |
现金转化率DXCMSCSC
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.87× | ||
| Q3 25 | 2.33× | 1.17× | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.74× | 3.79× | ||
| Q4 24 | 1.99× | -0.36× | ||
| Q3 24 | 1.48× | 2.64× | ||
| Q2 24 | 1.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
